Aktuellt
SENASTE
Redeye provides a research update following the Q4 report published by OncoZenge earlier today. The company manages to maintain a low OPEX and cash burn as the primary focus has been business development initiatives. With a new strategic partnership with Molteni Farmaceutici and a financing agreement with Yangtian Pharma, the company is now back on track with the upcoming phase III study in sight.
LÄS MER
